BELFAST-headquartered heart health technology company B-Secur has launched the latest evolution of its innovative HeartKey technology in a significant scaling of global operations to target the multi-billion-dollar consumer and healthcare markets.
The company, which doubled its workforce in recent months to over 75 employees and counts household consumer tech brands as well as world-leading semiconductor manufacturers as clients, launched its new cloud-based technology, HeartKey 2.0 in San Francisco last weekend.
The suite of FDA-cleared software reduces heart trace signal noise, elevating electrocardiogram (ECG) interpretation to new heights of efficiency and accuracy for clinicians and facilitating the growing trend towards greater remote cardiac monitoring through wearable devices
HeartKey 2.0, which also offers a range of diagnostic health algorithms, was unveiled on Friday at the Heart Rhythm expo, a cardiac medical conference attended by distinguished clinicians, scientists, researchers, and innovators.
B-Secur chief executive Alan Foreman said: “In 2021 we raised $12 million with the firm intention of accelerating our commercial expansion within the U.S.
“The launch of HeartKey 2.0 is an integral part of our expansion plans. The cloud-based technology helps strategically position us at the centre of the converging multi-billion-dollar consumer and medical device industries.
“B-Secur is going from strength to strength, we now employ over 75 highly skilled people, the majority of which are based in our Belfast headquarters.
“We are continuing in expansion mode and have heavily invested in a new brand and website which will continue to make us attractive partners for the biggest tech companies on the planet.
“We are proud to have achieved all of this from our home in Belfast and we are already working on exciting new plans which will see us continue to be anchored in this city.”
The latest HeartKey 2.0 technology refines and enhances signal clarity enabling ECG clinicians to make faster and more accurate diagnosis, speeding up the clinical pathway and saving more lives.
